Refine
Year of publication
Document Type
- Article (28)
- Conference Proceeding (3)
- Doctoral Thesis (1)
- Preprint (1)
Has Fulltext
- yes (33) (remove)
Is part of the Bibliography
- no (33)
Keywords
- polypharmacology (4)
- soluble epoxide hydrolase (3)
- PPARγ (2)
- Virtual Screening (2)
- allostery (2)
- farnesoid X receptor (2)
- non-alcoholic steatohepatitis (2)
- 3T3-L1 mouse fibroblasts (1)
- 5-lipoxygenase (1)
- AGMO (1)
- Anandamide (1)
- Arzneimitteldesign (1)
- Biochemistry (1)
- Biophysical chemistry (1)
- CCL2 (1)
- Cheminformatics (1)
- Cheminformatik (1)
- Chemoinformatics (1)
- Compound Database (1)
- Computational chemistry (1)
- De novo Design (1)
- Drug Design (1)
- Drug safety (1)
- FGFR (1)
- Free energy (1)
- HDAC4 (1)
- Identical Topology (1)
- Inflammation (1)
- Lead Structure (1)
- Metabolic syndrome (1)
- Molecular association (1)
- Molecular docking (1)
- Molekulare Bioinformatik (1)
- NAFLD (1)
- NASH (1)
- NCoR1 (1)
- NMR Spectroscopy (1)
- NR4A2 (1)
- Pairwise Sequence Alignment (1)
- Pharmacodynamics (1)
- Pharmazeutische Chemie (1)
- Physical and chemical properties (1)
- Polypharmacology (1)
- Proteins (1)
- RXRα (1)
- Rh(II) catalysis (1)
- SSR128129E (1)
- Structural biology (1)
- Target identification (1)
- Target validation (1)
- Virtuelles Screening (1)
- Wirkstoffdesign (1)
- adipocytes (1)
- cofactor recruitment (1)
- compound screen (1)
- designed multitarget ligands (1)
- diazo compounds (1)
- differential scanning fluorimetry (1)
- drug target (1)
- enzyme activity assay (1)
- fragment-based drug design (1)
- heterodimer (1)
- homodimer (1)
- homogeneous time-resolved FRET (HTRF) (1)
- inflammation (1)
- inhibitor (1)
- leukocyte-endothelial cell interaction (1)
- leukotriene A4 hydrolase (1)
- macrophage polarization (1)
- metabolic sydrome (1)
- metabolic syndrome (1)
- metallo β lactamases (1)
- montelukast (1)
- multi-target drug (1)
- multiresistant bacteria (1)
- multitarget drugs (1)
- neurodegeneration (1)
- non-alcoholic fatty liver disease (1)
- nuclear receptor (1)
- nuclear receptor-related 1 (1)
- peroxisome prolifer ators-activated receptor-γ (1)
- pharmacophore model (1)
- pranlukast (1)
- tetrahydrobiopterin (1)
- thiol inhibitors (1)
- transcription factor (1)
- zafirlukast (1)
Institute
- Biochemie und Chemie (17)
- Pharmazie (13)
- Biochemie, Chemie und Pharmazie (7)
- Biowissenschaften (5)
- Medizin (5)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (2)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (1)
- Georg-Speyer-Haus (1)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (1)
Dimerization of Taspase1 activates an intrinsic serine protease function that leads to the catalytic Thr234 residue, which allows to catalyze the consensus sequence Q−3X−2D−1⋅G1X2D3D4, present in Trithorax family members and TFIIA. Noteworthy, Taspase1 performs only a single hydrolytic step on substrate proteins, which makes it impossible to screen for inhibitors in a classical screening approach. Here, we report the development of an HTRF reporter assay that allowed the identification of an inhibitor, Closantel sodium, that inhibits Taspase1 in a noncovalent fashion (IC50 = 1.6 μM). The novel inhibitor interferes with the dimerization step and/or the intrinsic serine protease function of the proenzyme. Of interest, Taspase1 is required to activate the oncogenic functions of the leukemogenic AF4-MLL fusion protein and was shown in several studies to be overexpressed in many solid tumors. Therefore, the inhibitor may be useful for further validation of Taspase1 as a target for cancer therapy.
Designed multitarget ligands are a popular approach to generating efficient and safe drugs, and fragment-based strategies have been postulated as a versatile avenue to discover multitarget ligand leads. To systematically probe the potential of fragment-based multiple ligand discovery, we have employed a large fragment library for comprehensive screening on five targets chosen from proteins for which multitarget ligands have been successfully developed previously (soluble epoxide hydrolase, leukotriene A4 hydrolase, 5-lipoxygenase, retinoid X receptor, farnesoid X receptor). Differential scanning fluorimetry served as primary screening method before fragments hitting at least two targets were validated in orthogonal assays. Thereby, we obtained valuable fragment leads with dual-target engagement for six out of ten target combinations. Our results demonstrate the applicability of fragment-based approaches to identify starting points for polypharmacological compound development with certain limitations.
The bile acid activated transcription factor farnesoid X receptor (FXR) regulates numerous metabolic processes and is a rising target for the treatment of hepatic and metabolic disorders. FXR agonists have revealed efficacy in treating non-alcoholic steatohepatitis (NASH), diabetes and dyslipidemia. Here we characterize imatinib as first-in-class allosteric FXR modulator and report the development of an optimized descendant that markedly promotes agonist induced FXR activation in a reporter gene assay and FXR target gene expression in HepG2 cells. Differential effects of imatinib on agonist-induced bile salt export protein and small heterodimer partner expression suggest that allosteric FXR modulation could open a new avenue to gene-selective FXR modulators.